MSN, April 3, 2008 Vical Incorporated has been awarded a two-year, $2.0 million Phase II Small Business Technology Transfer grant from the U.S. National Institute of Allergy and Infectious Diseases. The grant will fund the ongoing development of Vical's immunotherapeutic plasmid DNA vaccine against herpes simplex virus type 2, the leading cause of genital herpes. The initial preclinical development activities covered by the grant will be conducted at UTMB and the University of Washington School of Medicine.